Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | -55.1x - -60.9x | -58.0x |
| Historical Pb Multiple | -102.1x - 141.4x | -46.6x |
| Fair Value | $5.42 - $5.99 | $5.70 |
| Upside | -46.1% - -40.4% | -43.3% |
| Benchmarks | - | Full Ticker |
| Bioventus Inc. | - | NasdaqGS:BVS |
| SI-BONE, Inc. | - | NasdaqGM:SIBN |
| Globus Medical, Inc. | - | NYSE:GMED |
| Orthofix Medical Inc. | - | NasdaqGS:OFIX |
| ZimVie Inc. | - | NasdaqGS:ZIMV |
| Alphatec Holdings, Inc. | - | NasdaqGS:ATEC |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| BVS | SIBN | GMED | OFIX | ZIMV | ATEC | |||
| NasdaqGS:BVS | NasdaqGM:SIBN | NYSE:GMED | NasdaqGS:OFIX | NasdaqGS:ZIMV | NasdaqGS:ATEC | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | -7.9% | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | -11.6% | NM- | NM- | NM- | ||
| Latest Twelve Months | 65.3% | 28.7% | -16.2% | 16.8% | 39.6% | 13.1% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -14.2% | -49.4% | 13.1% | -9.4% | -36.3% | -46.8% | ||
| Prior Fiscal Year | -18.9% | -31.2% | 7.8% | -20.3% | -12.3% | -38.7% | ||
| Latest Fiscal Year | -5.9% | -18.5% | 4.1% | -15.8% | -7.5% | -26.5% | ||
| Latest Twelve Months | -5.9% | -18.5% | 4.1% | -15.8% | -7.5% | -26.5% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | -15.5% | -38.4% | 7.6% | -12.5% | -7.0% | -587.2% | ||
| Prior Fiscal Year | -38.8% | -32.4% | 4.2% | -32.4% | -9.6% | -477.8% | ||
| Latest Twelve Months | -20.9% | -18.4% | 2.5% | -22.9% | -8.6% | -415.1% | ||
| Next Fiscal Year | 27.9% | -18.1% | 11.1% | -2.1% | 6.1% | 99.4% | ||
| Two Fiscal Years Forward | 27.4% | -16.2% | 11.5% | 3.2% | 6.4% | -61.2% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.9x | 3.3x | 3.7x | 0.7x | 0.6x | 2.4x | ||
| Price / LTM EPS | -15.1x | -17.9x | 91.7x | -4.4x | -7.8x | -8.9x | ||
| Price / Book | 3.4x | 3.3x | 2.3x | 1.1x | 0.7x | -102.1x | ||
| Price / Fwd Book | 2.7x | 4.2x | 2.2x | 1.2x | 0.7x | -34.4x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.7x | 2.3x | 3.4x | |||||
| Historical P/B Ratio | -102.1x | -46.6x | 141.4x | |||||
| Selected P/B Multiple | -55.1x | -58.0x | -60.9x | |||||
| (x) Book Value | (14) | (14) | (14) | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BVS | SIBN | GMED | OFIX | ZIMV | ATEC | |
| Value of Common Equity | 526 | 591 | 10,217 | 574 | 266 | 1,449 | |
| (/) Shares Outstanding | 66.2 | 42.5 | 137.5 | 39.0 | 27.7 | 144.1 | |
| Implied Stock Price | 7.95 | 13.92 | 74.28 | 14.72 | 9.60 | 10.05 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 7.95 | 13.92 | 74.28 | 14.72 | 9.60 | 10.05 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |